Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

Onno C. P. van Schayck; John Haughney; Michel Aubier; Olof Selroos; Tommy Ekstrom; Juliette Ostinelli; Roland Buhl

doi:10.1016/j.rmed.2011.10.017

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

Onno C. P. van Schayck^*, John Haughney, Michel Aubier, Olof Selroos, Tommy Ekstrom, Juliette Ostinelli, Roland Buhl

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Studies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics. Methods: EuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort (R) Turbuhaler (R))(h) maintenance and reliever therapy (Symbicort SMART (R)) at two maintenance doses of budesonide/formoterol (160/4.5 mu g), 1 x 2 and 2 x 2, in patients with asthma who were symptomatic despite treatment with ICS +/- long-acting beta(2)-agonists. The 8424 randomised patients included 886 smokers (11%; aged

Original language	English
Pages (from-to)	189-196
Journal	Respiratory Medicine
Volume	106
Issue number	2
DOIs	https://doi.org/10.1016/j.rmed.2011.10.017
Publication status	Published - Feb 2012

Keywords

ACQ-5
Asthma
Budesonide/formoterol maintenance and reliever therapy
Propensity-matched controls
Smokers
Symbicort SMART

Access to Document

10.1016/j.rmed.2011.10.017Licence: Free access - publisher

Cite this

@article{823767442e2446a09158f71963a883e7,

title = "Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study",

abstract = "Background: Studies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics. Methods: EuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort (R) Turbuhaler (R))(h) maintenance and reliever therapy (Symbicort SMART (R)) at two maintenance doses of budesonide/formoterol (160/4.5 mu g), 1 x 2 and 2 x 2, in patients with asthma who were symptomatic despite treatment with ICS +/- long-acting beta(2)-agonists. The 8424 randomised patients included 886 smokers (11%; aged ",

keywords = "ACQ-5, Asthma, Budesonide/formoterol maintenance and reliever therapy, Propensity-matched controls, Smokers, Symbicort SMART",

author = "{van Schayck}, {Onno C. P.} and John Haughney and Michel Aubier and Olof Selroos and Tommy Ekstrom and Juliette Ostinelli and Roland Buhl",

year = "2012",

month = feb,

doi = "10.1016/j.rmed.2011.10.017",

language = "English",

volume = "106",

pages = "189--196",

journal = "Respiratory Medicine",

issn = "0954-6111",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

AU - van Schayck, Onno C. P.

AU - Haughney, John

AU - Aubier, Michel

AU - Selroos, Olof

AU - Ekstrom, Tommy

AU - Ostinelli, Juliette

AU - Buhl, Roland

PY - 2012/2

Y1 - 2012/2

N2 - Background: Studies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics. Methods: EuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort (R) Turbuhaler (R))(h) maintenance and reliever therapy (Symbicort SMART (R)) at two maintenance doses of budesonide/formoterol (160/4.5 mu g), 1 x 2 and 2 x 2, in patients with asthma who were symptomatic despite treatment with ICS +/- long-acting beta(2)-agonists. The 8424 randomised patients included 886 smokers (11%; aged

AB - Background: Studies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics. Methods: EuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort (R) Turbuhaler (R))(h) maintenance and reliever therapy (Symbicort SMART (R)) at two maintenance doses of budesonide/formoterol (160/4.5 mu g), 1 x 2 and 2 x 2, in patients with asthma who were symptomatic despite treatment with ICS +/- long-acting beta(2)-agonists. The 8424 randomised patients included 886 smokers (11%; aged

KW - ACQ-5

KW - Asthma

KW - Budesonide/formoterol maintenance and reliever therapy

KW - Propensity-matched controls

KW - Smokers

KW - Symbicort SMART

U2 - 10.1016/j.rmed.2011.10.017

DO - 10.1016/j.rmed.2011.10.017

M3 - Article

C2 - 22119455

SN - 0954-6111

VL - 106

SP - 189

EP - 196

JO - Respiratory Medicine

JF - Respiratory Medicine

IS - 2

ER -

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

Abstract

Keywords

Access to Document

Fingerprint

Cite this